Advanced Microbubbles logo

Advanced Microbubbles

Niche

Advanced Microbubbles develops ultrasound-activated microbubble technology for targeted drug and gene delivery, with a primary focus on oncology; microbubbles encapsulate therapeutic agents and release them precisely at tumor sites via focused.

Best for: Ultrasound-Triggered Microbubble Drug Delivery
Life Sciences & BioTechUltrasound-Triggered Microbubble Drug DeliveryWebsiteUpdated May 2026

Company Overview

About Advanced Microbubbles

Advanced Microbubbles Inc. is a biomedical technology company developing ultrasound-triggered microbubble platforms for targeted drug and gene delivery, with a primary therapeutic focus on cancer treatment. The company's core technology involves engineering microscopic gas-filled bubbles that can be loaded with chemotherapy drugs, gene therapy vectors, or other therapeutic payloads. When these microbubbles circulate through the bloodstream and reach the target tissue (such as a tumor), focused ultrasound is applied externally to cause the bubbles to oscillate and rupture — releasing the therapeutic payload precisely at the intended site with minimal systemic exposure.

Business Model & Competitive Advantage

This targeted delivery approach addresses one of the central challenges in oncology: conventional chemotherapy distributes toxic drugs throughout the body, causing severe side effects while delivering subtherapeutic concentrations at the actual tumor. Ultrasound-triggered microbubble delivery achieves localized drug release, concentrating the therapeutic effect at the tumor while sparing healthy tissue. The technology also has the potential to transiently open the blood-brain barrier in a localized, reversible manner — a breakthrough capability for treating brain tumors and neurological diseases where the blood-brain barrier prevents most drugs from reaching the brain.

Competitive Landscape 2025–2026

Advanced Microbubbles is at a pre-clinical or early clinical research stage, working to demonstrate safety and efficacy in animal models and early human studies. The field of therapeutic microbubbles is actively being pursued by academic medical centers and companies including Bracco (a leader in diagnostic ultrasound contrast agents), Insightec (focused ultrasound company), and various university spin-outs. The company's work represents a convergence of medical imaging, ultrasound physics, drug formulation, and oncology biology.

Curated content • Fact-checked and verified

Frequently Asked Questions

Similar Brands

Neuralink logo

Neuralink

Life Sciences & BioTech
HealthtechHardwareAi PoweredB2b2cStartupDecacornNorth AmericaTechnologyPlatformEnterprise

Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa

Pliant Therapeutics logo

Pliant Therapeutics

BioTech
HealthtechTechnologyPublicB2bStartup

Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclero

Illumina logo

Illumina

Life Sciences & BioTech
B2bGlobalPublicEnterpriseHealthtechAnalyticsHardwarePlatformFortune500

Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat

Cradle logo

Cradle

Life Sciences & BioTech
HealthtechSaasNorth AmericaB2b

Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, acti

BioNTech logo

BioNTech

Life Sciences & BioTech
B2bGlobalPublicEnterpriseHealthtechManufacturingPlatform

BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere

Genentech logo

Genentech

Life Sciences & BioTech
B2bGlobalEnterprisePublicHealthtechManufacturingFortune500

Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching

For Advanced Microbubbles

Claim This Profile

Are you from Advanced Microbubbles? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.

Claim Advanced Microbubbles Profile →
For competitors & analysts

Track AI Visibility in Real Time

Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Advanced Microbubbles vs competitors. Get alerts when AI recommendations shift.

Start Free Tracking →